• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对两株对美罗培南敏感性降低但对亚胺培南敏感性未降低的肺炎克雷伯菌菌株进行孔蛋白缺陷突变体的体外筛选。

In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem.

作者信息

Pragai Z, Nagy E

机构信息

Department of Clinical Microbiology, Albert Szent-Györgyi Medical University, Hungary.

出版信息

J Antimicrob Chemother. 1998 Dec;42(6):821-4. doi: 10.1093/jac/42.6.821.

DOI:10.1093/jac/42.6.821
PMID:10052909
Abstract

We have evaluated the ability of imipenem and meropenem to select, in vitro, resistant mutants of two clinical isolates of Klebsiella pneumoniae producing both SHV and TEM beta-lactamases. Only meropenem selected mutants of both isolates for which the MICs of meropenem, but not imipenem, were markedly higher than those for the parent strains; the MICs of several other beta-lactam antibiotics, including beta-lactam/beta-lactamase inhibitor combinations, for these mutants were also higher than those for the parent strains. In contrast, the MICs for the imipenem-selected mutants were the same as, or similar to, those for the parent strains. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis analysis revealed that an outer membrane protein in both parent strains was absent in the meropenem-selected mutants, but not in the imipenem-selected mutants. This protein is likely to be a porin, the absence of which is presumably associated with impaired beta-lactam permeability and, therefore, the reduced susceptibilities to these antibiotics exhibited by the mutant strains. We believe that this is the first report of the in-vitro selection of porin-deficient mutants of K. pneumoniae following exposure to meropenem.

摘要

我们评估了亚胺培南和美罗培南在体外对两株产 SHV 和 TEM β-内酰胺酶的肺炎克雷伯菌临床分离株选择耐药突变体的能力。只有美罗培南选择出了两株分离株的突变体,这些突变体对美罗培南的最低抑菌浓度(MIC)显著高于亲本菌株,而对亚胺培南的 MIC 则不然;包括β-内酰胺/β-内酰胺酶抑制剂组合在内的其他几种β-内酰胺类抗生素对这些突变体的 MIC 也高于亲本菌株。相比之下,亚胺培南选择出的突变体的 MIC 与亲本菌株相同或相似。十二烷基硫酸钠-聚丙烯酰胺凝胶电泳分析显示,两种亲本菌株中的一种外膜蛋白在美罗培南选择出的突变体中缺失,但在亚胺培南选择出的突变体中未缺失。这种蛋白可能是一种孔蛋白,其缺失可能与β-内酰胺通透性受损有关,因此突变菌株对这些抗生素的敏感性降低。我们认为,这是首次报道肺炎克雷伯菌在体外暴露于美罗培南后选择出孔蛋白缺陷突变体的情况。

相似文献

1
In-vitro selection of porin-deficient mutants of two strains of Klebsiella pneumoniae with reduced susceptibilities to meropenem, but not to imipenem.对两株对美罗培南敏感性降低但对亚胺培南敏感性未降低的肺炎克雷伯菌菌株进行孔蛋白缺陷突变体的体外筛选。
J Antimicrob Chemother. 1998 Dec;42(6):821-4. doi: 10.1093/jac/42.6.821.
2
Prevalence and mechanisms of decreased susceptibility to carbapenems in Klebsiella pneumoniae isolates.肺炎克雷伯菌分离株对碳青霉烯类药物敏感性降低的发生率及机制
Diagn Microbiol Infect Dis. 2007 Jan;57(1):85-91. doi: 10.1016/j.diagmicrobio.2006.05.008. Epub 2006 Jul 18.
3
Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.产 KPC 肺炎克雷伯菌中美罗培南-沃博巴坦耐药选择、耐药预防及突变体的分子机制
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01694-17. Print 2017 Dec.
4
Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.头孢吡肟和碳青霉烯类药物对产FOX-5β-内酰胺酶的孔蛋白缺陷型肺炎克雷伯菌所致实验性肺炎的活性。
Clin Microbiol Infect. 2005 Jan;11(1):31-8. doi: 10.1111/j.1469-0691.2004.01018.x.
5
Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.产超广谱β-内酰胺酶肺炎克雷伯菌和大肠埃希菌对亚胺培南或美罗培南耐药的流行率及其影响因素。
Diagn Microbiol Infect Dis. 2011 Sep;71(1):87-9. doi: 10.1016/j.diagmicrobio.2010.12.012. Epub 2011 Mar 11.
6
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.产厄他培南耐药超广谱β-内酰胺酶的肺炎克雷伯菌克隆携带一种新型的 OmpK36 孔蛋白变体。
Antimicrob Agents Chemother. 2010 Oct;54(10):4178-84. doi: 10.1128/AAC.01301-09. Epub 2010 Jul 26.
7
Imipenem- and meropenem-resistant mutants of Enterobacter cloacae and Proteus rettgeri lack porins.阴沟肠杆菌和雷氏变形杆菌对亚胺培南和美罗培南耐药的突变体缺乏孔蛋白。
Antimicrob Agents Chemother. 1991 Jun;35(6):1174-80. doi: 10.1128/AAC.35.6.1174.
8
The Role of OmpK35, OmpK36 Porins, and Production of β-Lactamases on Imipenem Susceptibility in Klebsiella pneumoniae Clinical Isolates, Cairo, Egypt.埃及开罗肺炎克雷伯菌临床分离株中OmpK35、OmpK36孔蛋白及β-内酰胺酶产生对亚胺培南敏感性的作用
Microb Drug Resist. 2015 Dec;21(6):577-80. doi: 10.1089/mdr.2014.0226. Epub 2015 May 6.
9
Carbapenem and cefoxitin resistance of Klebsiella pneumoniae strains associated with porin OmpK36 loss and DHA-1 β-lactamase production.产碳青霉烯酶肺炎克雷伯菌与孔蛋白 OmpK36 缺失和 DHA-1 型β-内酰胺酶产生相关,表现出对碳青霉烯类和头孢西丁的耐药性。
Braz J Microbiol. 2013 Oct 30;44(2):435-42. doi: 10.1590/S1517-83822013000200015. eCollection 2013.
10
Study of Synergistic Bactericidal Activity of Dual β-Lactam Antibiotics Against KPC-2-Producing .产 KPC-2 酶肠杆菌科细菌中两种β-内酰胺类抗生素协同杀菌活性的研究
Microb Drug Resist. 2020 Mar;26(3):204-210. doi: 10.1089/mdr.2019.0126. Epub 2019 Sep 25.

引用本文的文献

1
High-level carbapenem resistance in a Klebsiella pneumoniae clinical isolate is due to the combination of bla(ACT-1) beta-lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin phoe.肺炎克雷伯菌临床分离株中的高水平碳青霉烯耐药性是由bla(ACT-1)β-内酰胺酶产生、孔蛋白OmpK35/36插入失活以及磷酸盐转运孔蛋白phoe的下调共同导致的。
Antimicrob Agents Chemother. 2006 Oct;50(10):3396-406. doi: 10.1128/AAC.00285-06.
2
Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.从一株耐碳青霉烯类的肺炎克雷伯菌中分离出的新型碳青霉烯水解β-内酰胺酶KPC-1
Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61. doi: 10.1128/AAC.45.4.1151-1161.2001.
3
Meropenem: an updated review of its use in the management of intra-abdominal infections.美罗培南:其在腹腔内感染管理中应用的最新综述
Drugs. 2000 Sep;60(3):619-46. doi: 10.2165/00003495-200060030-00010.
4
Meropenem: a review of its use in patients in intensive care.美罗培南:对其在重症监护患者中应用的综述
Drugs. 2000 Mar;59(3):653-80. doi: 10.2165/00003495-200059030-00016.